L3VLUP
ProSign in

ARGX · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARGXAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARGX
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterARGXAMGN
Q3 20208 holders, $3.6bn16 holders, $16.3bn
Q4 20207 holders, $4.1bn19 holders, $14.0bn
Q1 20218 holders, $4.1bn16 holders, $14.5bn
Q2 20219 holders, $4.6bn23 holders, $13.8bn
Q3 20218 holders, $4.5bn24 holders, $11.6bn
Q4 20219 holders, $5.3bn21 holders, $10.4bn
Q1 20228 holders, $5.3bn23 holders, $9.9bn
Q2 202213 holders, $6.5bn28 holders, $9.7bn
Q3 202214 holders, $5.3bn21 holders, $7.9bn
Q4 202213 holders, $5.5bn24 holders, $9.3bn
Q1 202313 holders, $5.9bn22 holders, $8.4bn
Q2 202318 holders, $6.6bn26 holders, $7.4bn
Q3 202321 holders, $8.7bn26 holders, $8.7bn
Q4 202317 holders, $6.3bn24 holders, $8.4bn
Q1 202413 holders, $6.8bn25 holders, $6.7bn
Q2 202414 holders, $7.9bn20 holders, $8.0bn
Q3 202413 holders, $10.7bn21 holders, $8.8bn
Q4 202414 holders, $12.3bn20 holders, $8.2bn
Q1 202517 holders, $11.8bn25 holders, $12.0bn
Q2 202518 holders, $10.8bn20 holders, $10.2bn
Q3 202516 holders, $13.8bn17 holders, $10.4bn
Q4 202516 holders, $14.8bn19 holders, $18.0bn
Q1 202611 holders, $12.3bn15 holders, $21.4bn
Q2 202614 holders, $15.0bn23 holders, $24.9bn
ARGX

Argenx Se

Holders
14
Reported value
$15.0bn
Buyers
16
Sellers
15

Breadth +1 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
23
Reported value
$24.9bn
Buyers
19
Sellers
13

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARGX (3)

Artisan Partners LP, Baillie Gifford & Co, Voloridge Investment Management LLC

Only AMGN (12)

Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Hudson Bay Capital Management LP, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, PDT Partners LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →